Medicare’s ESA Proposal Relies Too Much On Off-Label Data, Amgen Says

CMS improperly applies safety data from off-label uses of erythropoiesis-stimulating agents to chemotherapy-induced anemia in its recent proposed national coverage determination on ESAs, Amgen maintains